Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217839 | 1.00 | AGBL2 (0.31) | AGBL2ADAMTS4MMP1MMP13MMP14 | |
| SCHEMBL347642 | 0.80 | APLNR (0.43) | KCNH2APLNR | |
| SCHEMBL588484 | 0.80 | APLNR (0.43) | KCNH2APLNR | |
| SCHEMBL588486 | 0.80 | APLNR (0.43) | KCNH2APLNR | |
| SCHEMBL590717 | 0.79 | AGBL2 (0.34) | AGBL2 | |
| SCHEMBL30615155 | 0.79 | AGBL2 (0.34) | AGBL2 | |
| SCHEMBL3613440 | 0.71 | IDH1 (0.33) | — | |
| SCHEMBL347036 | 0.69 | P2RX7 (0.40) | — | |
| SCHEMBL22587371 | 0.69 | ESR1 (0.42) | — | |
| SCHEMBL22587369 | 0.69 | ESR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| US-8835465-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2014-09-16 | — | — | US | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| US-8324252-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2012-12-04 | — | — | US | disclosed |
| US-20120071480-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA R&D (SE) | 2012-03-22 | — | — | US | disclosed |
| US-8088784-B2 | 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| EP-2388259-A1 | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | AstraZeneca AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| US-8040733-B2 | Non-volatile memory device and method of operating the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| EP-2152702-B1 | AMINO-THIAZOLYL- PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2011-08-24 | — | — | EP | disclosed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-12-23 | — | — | US | disclosed |
| US-20100160325-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | CNKSR1, LTK, MUSK | AGBL2 2995/4885ADAMTS4 1833/4885MMP1 1768/4885 |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K2 | AGBL2 2369/4885ADAMTS4 4574/4885MMP1 4754/4885 |
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ABL1, FLT3, ERBB2 | AGBL2 2054/4885ADAMTS4 4345/4885MMP1 4840/4885 |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | AGBL2 3705/4885ADAMTS4 3862/4885MMP1 4410/4885 |
| US-20120071480-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ABL1, FLT3, ERBB2 | AGBL2 1955/4885ADAMTS4 4382/4885MMP1 4838/4885 |
| US-20100160325-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ABL1, FLT3, ERBB2 | AGBL2 2054/4885ADAMTS4 4345/4885MMP1 4840/4885 |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | AGBL2 3000/4885ADAMTS4 1459/4885MMP1 4678/4885 |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, MPL, MCL1 | AGBL2 4265/4885ADAMTS4 4739/4885MMP1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.